Triple negative breast cancer
Conditions
Interventions
experimental group :Anlotinib hydrochloride + Neoadjuvant chemotherapy
Sponsors
The Second Affiliated Hospital of Xi'an Jiaotong University
Eligibility
Sex/Gender
Female
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Patients voluntarily participate in this study; 2. Patients with locally advanced triple-negative breast cancer (stage IIB, IIIA, IIIB, and IIIC) diagnosed by pathology; 3. Have not received any anti-tumor treatment (including any form of chemotherapy, radiotherapy, and Chinese medicine treatment) within at least one month before treatment; 4. Hemoglobin (HB) >= 90g/L; 5. The absolute value of neutrophils (ANC) >=1.5x10^9/L; 6. Platelets (PLT) >=80x10^9/L; 7. Total bilirubin (TBIL) = 60ml/min.
Exclusion criteria
Exclusion criteria: 1. Received radiotherapy, chemotherapy and targeted therapy within at least one month before enrollment; 2. Concomitant with other malignant diseases or diagnosed with other malignant diseases within 5 years before enrollment; 3. Patients who have used Anlotinib Hydrochloride Capsules in the past; 4. Patients with any severe or uncontrolled disease; 5. There are many factors that affect oral drugs (such as: inability to swallow, chronic diarrhea, intestinal obstruction, etc.); 6. Participated in other anti-tumor drug clinical trials within four weeks; 7. Arterial/venous thrombosis occurred within 6 months; 8. According to the investigator's judgment, the tumor is very likely to invade important blood vessels and cause fatal bleeding during the follow-up trial; 9. According to the judgment of the investigator, there is a concomitant disease that seriously endangers the safety of the patient or affects the completion of the trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pathological complete remission; | — |
Secondary
| Measure | Time frame |
|---|---|
| Progression-free survival;Objective response rate;safety; | — |
Countries
China
Contacts
Public ContactShuqun Zhang
Outcome results
None listed